

# NextCell in Swedish Life Science Delegation to Hong Kong

NextCell Pharma AB (“NextCell” or “the Company”) is participating in the Swedish life science delegation to Hong Kong on 10–12 December 2025, organised by the Hong Kong Chamber of Commerce in Sweden and the Hong Kong Biotechnology Organisation (HKBIO). The delegation brings together leading Swedish companies to deepen collaborations in research, clinical development, industrial production, and investment in Hong Kong and the Greater Bay Area (GBA).

Hong Kong is rapidly positioning itself as an international hub for regulatory innovation, clinical research, and capital markets, while serving as a strategic and operational access point to China and the GBA — a region of 87 million inhabitants and one of the world’s fastest-growing life science ecosystems.

“Hong Kong represents a highly interesting bridge into China, both from a regulatory and commercial perspective. NextCell is actively exploring the possibility of establishing a presence in the region as a future pathway for clinical development and partnerships in the Chinese market,” says Mathias Svahn, CEO of NextCell Pharma.

The delegation includes meetings with Hong Kong’s Innovation, Technology and Industry Bureau (ITIB), Invest Hong Kong, Hong Kong Science & Technology Parks (HKSTP), and Hong Kong Exchanges and Clearing (HKEX), with a focus on regulatory opportunities, clinical collaborations, and investor relations.

## For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Tel: 0+46 8-735 5595

E-mail: [info@nextcellpharma.com](mailto:info@nextcellpharma.com)

Website: [www.nextcellpharma.com](http://www.nextcellpharma.com)

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

## Certified Adviser

The company's shares are listed on the Nasdaq First North Growth Market.

RedEye AB is assigned as Certified Adviser.

## About NextCell Pharma AB

NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) from umbilical cord. Using a proprietary selection algorithm, ProTrans delivers optimised cell tailored to specific indications. In type 1 diabetes, a single infusion has been shown to preserve insulin production and delay disease progression for at least five

years. A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being evaluated for other autoimmune and inflammatory conditions. NextCell's subsidiaries include Cellaviva, Scandinavia's largest private stem cell bank, and QVance, the Nordic region's first dedicated provider of quality services for developers of advanced therapies.